Not yet recruiting
A Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC
2026-526300-67-00· Phase 3· Summit Therapeutics Inc.· Source
Not yet recruiting
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
NCT07873801· Phase 3· Almirall, S.A.· Source
Not yet recruiting
A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)
2025-522648-42-01· Phase 2/3· Crinetics Pharmaceuticals Inc.· Source
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· Phase 3· AstraZeneca· Source
Not yet recruiting
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.
2026-525883-17-00· Phase 3· Genmab A/S· Source
Recruiting
Dose Escalation Study to Assess Safety, Tolerability, and Efficacy of Budiodarone Treatment With Non-permanent Atrial Fibrillation
NCT07792239· Phase 2· Xyra, LLC· Source
Not yet recruiting
A Randomized, Double-Blind, Phase 2 Trial Evaluating the Efficacy, Safety and Tolerability of Primary Cardioprotection with Dapagliflozin in Patients with Newly Diagnosed Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
2026-525418-67-00· Phase 2· Instytut Hematologii I Transfuzjologii· Source
Recruiting
Proof-of-Concept Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of Intranasal Cenegermin in Adult Participants with moderate to severe Traumatic Brain Injury (TBI).
2025-522692-29-00· Phase 2· Dompe' Farmaceutici S.p.A.· Source
Recruiting
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
NCT07318610· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])
NCT07666490· Phase 4· Chiesi Farmaceutici S.p.A.· Source
Recruiting
A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
2025-522818-23-00· Phase 3· Zai Lab (US) LLC· Source
Recruiting
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
2025-521587-35-00· Phase 3· Summit Therapeutics Inc.· Source
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181· Phase 2· Boehringer Ingelheim· Source
Recruiting
A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
NCT07503873· Phase 2· TG Therapeutics, Inc.· Source
Recruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source
Recruiting
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
NCT07201129· Phase 3· Viatris Innovation GmbH· Source
Active, not recruiting
A study to learn about how well BAY 3401016 works in adults with Alport syndrome
2024-516471-33-00· Phase 2· Bayer AG· Source
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· Phase 3· Eli Lilly and Company· Source
Contact: Szymon Borowiec (principal investigator)
Active, not recruiting
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
NCT07160608· Phase 2· Alexion Pharmaceuticals, Inc.· Source
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751· Phase 3· BioNTech SE· Source
Recruiting
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
NCT06486883· Phase 2· MedSIR· Source
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Evaluation of the efficacy and safety of dual biologic and/or small molecule therapy in patients with induction-resistant ulcerative colitis (RESPECT).
2023-506628-98-00· Phase 2· Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy· Source
Active, not recruiting
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study
NCT06914908· Phase 2· Sanofi· Source
Recruiting
BOOSTER – Multicenter, Open Label, Randomized Control Phase III Trial Comparing the Efficacy and Safety of Two Rituximab Regimens in Maintenance Therapy for Relapsing Nephrotic Syndrome Due to Podocytopathies in Adults.
(B cell Depletion Therapy to Improve Outcomes of Relapsing STERoid-sensitive Podocytopathies in Adults – BOOSTER trial)
2023-509755-13-00· Phase 3· Medical University Of Lodz· Source
Recruiting
A randomized trial comparing efficacy and safety of etanercept and methotrexate in giant
cell arteritis (EFFECTA)
2023-506623-29-01· Phase 2· Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy· Source
Recruiting
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949· Phase 3· Amgen· Source
Active, not recruiting
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347· Phase 3· Sanofi· Source
Recruiting
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
2022-502352-31-00· Phase 3· Amgen Inc.· Source
Recruiting
Treatment of acute ischemic stroke due to occlusion of a large vessel by mechanical thrombectomy in patients with unknown onset or not meeting the criteria for CT eligibility (ASPECTS <6) based on MRI criteria (DWIFLAIR mismatch)
2024-515062-13-00· Phase 3· Medical University Of Gdansk· Source
Recruiting
Tandem therapy LutaPol/ltraPol ( I 77Lu / 90Y-DOTATATE) as an effective method in the treatment of neuroendocrine neoplasmas.
2024-516503-17-01· Phase 3· Narodowe Centrum Badan Jadrowych· Source
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· Phase 2/3· BioNTech SE· Source
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647· Phase 3· AstraZeneca· Source
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738· Phase 3· AstraZeneca· Source
Recruiting
"MetCool ACS"- Metformin "Cooling" Effect on metformin-naive Patients Treated with PCI because of Acute Coronary Syndrome
2024-516589-13-00· Phase 3· Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy· Source
Recruiting
EXtensive mulTilayer stEnt treatmeNt in Aortic disSectiOn
NCT06675617· Intressa Vascular SA· Source
Contact: Virginie Martin
Active, not recruiting
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
NCT06598462· Phase 2· Uniquity One (UNI)· Source
Recruiting
Absolute quantification of myocardial blood flow in human subjects with SYN2 dynamic PET imaging
2023-507520-23-00· Phase 2· Synektik S.A.· Source
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649· Phase 3· Amgen· Source
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995· Phase 3· Eli Lilly and Company· Source
Recruiting
Platform Clinical Study for Conquering Scleroderma
NCT06195072· Phase 2· Scleroderma Research Foundation, Inc.· Source
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392· Phase 3· AstraZeneca· Source
Recruiting
A Phase III Prospective, Multicenter, Open-label Study to Assess Diagnostic Efficacy of a Novel 18F-labelled Tracer, SYN2, for Positron Emission Tomography in Subjects with Suspected Coronary Artery Disease
2023-506971-89-00· Phase 3· Syn2bio S.A.· Source
Active, not recruiting
Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
2023-503428-24-00· Phase 2· Glaxosmithkline Research & Development Limited· Source
Active, not recruiting
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.
2022-501622-37-00· Phase 3· Celltrion Inc.· Source
Recruiting
A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of RVU120 in Combination with Venetoclax in Participants with Acute Myeloid Leukemia Who Failed Prior Therapy with Venetoclax and a Hypomethylating Agent (RIVER-81)
2023-505911-19-00· Phase 2· Ryvu Therapeutics S.A.· Source
Active, not recruiting
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
NCT05835986· Phase 1· Hoffmann-La Roche· Source
Active, not recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608· Phase 3· Summit Therapeutics· Source
Showing 50 of 70.